Clinical Trials
2 trialsNCT02718911 2023-10-16
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT02737072 2019-08-12
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated